Evidence map›Paper›PMID 42783212›Full record

ArticleDiseases (Basel, Switzerland)2026

Sequential Application of Time-Stratified Demographic, Vital, Clinical-Laboratory, and Microbiology Variables for Accurate and Rapid Identification of Sepsis.

Krupa Arun Navalkar, José Garnacho-Montero, María Luisa Cantón-Bulnes, José Luís García-Garmendia, Ángel Estella, Adela Fernández-Galilea, Isidro Blanco, Maria Antonia Estecha-Foncea, Marina Gordillo-Resina, Jorge Rodríguez-Gómez and 21 more

Abstract read
In one paragraph

Article in Diseases (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Krupa Arun NavalkarImmunexpress Inc., Seattle, WA 98109, USA.ORCID 0000-0002-4751-6130
José Garnacho-MonteroIntensive Care Unit, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.ORCID 0000-0003-2542-7601
María Luisa Cantón-BulnesIntensive Care Unit, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain.ORCID 0000-0003-1024-2954
José Luís García-GarmendiaIntensive Care Unit, Hospital San Juan de Dios del Aljarafe, 41930 Sevilla, Spain.ORCID 0000-0003-1443-9236
Ángel EstellaIntensive Care Unit, Hospital Universitario de Jerez de la Frontera, 11407 Cádiz, Spain.ORCID 0000-0003-0665-557X
Adela Fernández-GalileaIntensive Care Unit, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.ORCID 0000-0002-4859-3293
Isidro BlancoIntensive Care Unit, Hospital Universitario de Jerez de la Frontera, 11407 Cádiz, Spain.
Maria Antonia Estecha-FonceaIntensive Care Unit, Hospital Universitario Virgen de la Victoria (Málaga), 29010 Málaga, Spain.
Marina Gordillo-ResinaIntensive Care Unit, Hospital Universitario Virgen de la Victoria (Málaga), 29010 Málaga, Spain.
Jorge Rodríguez-GómezIntensive Care Unit, Hospital Universitario Reina Sofía (Córdoba), 14004 Córdoba, Spain.
Juan Jesús Pineda-CapitánIntensive Care Unit, Hospital Universitario Reina Sofía (Córdoba), 14004 Córdoba, Spain.
Carmen Martínez-FernándezIntensive Care Unit, Hospital San Juan de Dios del Aljarafe, 41930 Sevilla, Spain.
Ana Escoresca-OrtegaIntensive Care Unit, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
Rosario Amaya-VillarIntensive Care Unit, Hospital Universitario Virgen del Rocío, 41013 Sevilla, Spain.
Juan Mora-OrdóñezIntensive Care Unit, Hospital Universitario Regional de Málaga (Málaga), 29010 Málaga, Spain.
Sara González-SotoIntensive Care Unit, Hospital Universitario Regional de Málaga (Málaga), 29010 Málaga, Spain.
Antonio Gutierrez-PizarrayaAgencia Andaluza de Evaluación de Tecnología Sanitaria, 41092 Sevilla, Spain.
Robert BalkRush Medical College and Rush University Medical Center, Chicago, IL 60612, USA.ORCID 0000-0001-5757-2649
Russell R MillerFirstHealth of the Carolinas, Pinehurst, NC 28374, USA.
John P BurkeIntermountain Medical Center, Murray, UT 84107, USA.
Gourang PatelDepartment of Pharmacy Services, University of Chicago Medicine, Chicago, IL 60637, USA.
Jorge P ParadaLoyola University Medical Center, Maywood, IL 60153, USA.
Marcus J SchultzDivision of Cardiothoracic and Vascular Anaesthesia & Critical Care Medicine, Department of Anaesthesia, General Intensive Care and Pain Management, Medical University Wien, 1090 Vienna, Austria.ORCID 0000-0003-3969-7792
Brendon P SciclunaCentre for Molecular Medicine and Biobanking, University of Malta, MSD 2080 Msida, Malta.ORCID 0000-0003-2826-0341
Emily BlodgetKeck Hospital of University of Southern California (USC), Los Angeles, CA 90033, USA.
Santhi KumarKeck Hospital of University of Southern California (USC), Los Angeles, CA 90033, USA.ORCID 0000-0003-0981-4222
Dayle SampsonElysium Health, 434 Broadway, New York, NY 10013, USA.
Thomas D YagerImmunexpress Inc., Seattle, WA 98109, USA.ORCID 0000-0002-2341-2353
Roy F DavisImmunexpress Inc., Seattle, WA 98109, USA.
Silvia CermelliImmunexpress Inc., Seattle, WA 98109, USA.
Richard B BrandonImmunexpress Inc., Seattle, WA 98109, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAccurate early identification of sepsis remains a major clinical challenge due to its heterogeneous presentation and overlap of clinical signs with the non-infectious systemic inflammatory response syndrome (SIRS). Timely differentiation is crucial for improving patient outcomes, meeting sepsis bundle requirements and reducing inappropriate antimicrobial use. We hypothesized that clinical-laboratory data available within the first three hours of patient presentation could be used to identify patients with sepsis at a clinically useful level of diagnostic accuracy, in lieu of traditional microbiology results which would not become available until at least 12-24 h. Data from two independent studies were used to quantify the diagnostic value of demographic, vital, clinical-laboratory, and microbiological data available at three time points for distinguishing retrospectively diagnosed critically ill patients with either sepsis or non-infectious SIRS. A particular focus of this work was an assessment of the utility of SeptiCyte RAPID (Immunexpress Inc., Seattle, WA, USA) as an aid to sepsis diagnosis, producing actionable data within one hour.

methodsData from two independent study cohorts were analyzed. The "510(k) cohort" consisted of 419 adult patients in intensive care (ICU) (MARS, VENUS, and NEPTUNE studies). The "Andalusian cohort" consisted of 353 ICU patients from the PANGEA study. Logistic regression models, selected by a greedy search algorithm and validated by repeated cross-validation, were used to determine the contributions of different variables to diagnostic accuracy. Diagnostic performance was quantified by the area under the receiver operating characteristic curve (AUC).

resultsFor the 510(k) cohort, a baseline AUC of 0.69-0.73 was observed using five to seven vital and demographic variables assessed immediately upon presentation (time T1). The addition of clinical-laboratory variables, in particular SeptiCyte RAPID, within one to three hours post-presentation (time T2) increased the AUC to 0.85-0.86. Finally, the addition of microbiological data 12-24 h post-presentation (time T3) further improved the AUC to 0.90-0.91. Similar results were obtained for the Andalusian cohort. AUC values at the three time points were as follows: At time T1, AUC = 0.67 based solely on vital signs and demographics; at time T2, AUC = 0.87 based on vitals + demographics + SeptiCyte RAPID ± other clinical-laboratory data; at time T3, AUC = 0.93 based on vitals + demographics + SeptiCyte RAPID ± other clinical-laboratory data + microbiology results. For both cohorts, the most significant variables included temperature, mean arterial pressure, respiratory rate, suspected infection site, SeptiCyte RAPID, procalcitonin, confirmed bacterial infection and positive blood culture confirmation. In summary, the AUC for diagnosing sepsis rose progressively from T1 (510(k) 0.69-0.73; Andalusian 0.67) to T2 (510(k) 0.85-0.86; Andalusian 0.87) with the addition of SeptiCyte RAPID to T3 (510(k) 0.90-0.91; Andalusian 0.93) as more clinical information became available over time.

conclusionsThe accuracy of identification of sepsis increases markedly as demographics and vital signs are supplemented with clinical-laboratory information, and ultimately with microbiological culture results. The AUC improves in the shortest time within the first three hours when laboratory data, and particularly SeptiCyte RAPID results, become available. Integrating rapid host response testing with SeptiCyte RAPID into time-based diagnostic frameworks may enhance early sepsis recognition, improve antimicrobial stewardship, and support guideline-driven clinical decisions.

Indexed as

diagnostic accuracyearly diagnosishost response assayintensive carelogistic regressionprocalcitoninsepsisSeptiCyte RAPIDsystemic inflammatory response syndrome (SIRS)temporal analysis

Identifiers

PMID42783212
PMCPMC13605279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.